We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Non-Invasive Skin Swab Samples Enough to Quickly Detect COVID-19, Finds New Study

By LabMedica International staff writers
Posted on 17 Mar 2021
Illustration
Illustration
Non-invasive skin swab samples are enough to quickly detect COVID-19, according to findings of a new study.

In the study, researchers at the University of Surrey (Guildford, Surrey, UK), collected sebum samples from 67 hospitalized patients - 30 who had tested positive for COVID-19 and 37 who had tested negative. The samples were collected by gently swabbing a skin area rich in sebum - an oily, waxy substance produced by the body's sebaceous glands - such as the face, neck or back. The researchers analyzed the samples by using liquid chromatography mass spectrometry and a statistical modeling technique called Partial Least Squares - Discriminant Analysis to differentiate between the COVID-19 positive and negative samples.

The team then found that patients with a positive COVID-19 test had lower lipid levels - or dyslipidemia - than their counterparts with a negative test. The accuracy of the study’s results increased further when medication and additional health conditions were controlled.

"Unfortunately, the specter of future pandemics is firmly on the top of the agenda for the scientific community. Our study suggests that we may be able to use non-invasive means to test for diseases such as COVID-19 in the future - a development which I am sure will be welcomed by all," said Dr. Melanie Bailey, co-author of the study from the University of Surrey.

"COVID-19 damages many areas of metabolism. In this work, we show that the skin lipidome can be added to the list, which could have implications for the skin’s barrier function, as well as being a detectable symptom of the disease itself," added Matt Spick, co-author of the study from the University of Surrey.

"Investigating new methods of diagnosis and surveillance in a new disease such as COVID-19 that has had such a devastating effect on the world is vital. Sebum sampling is a simple, non-invasive method that shows promise for both diagnostics and monitoring of the disease in both a healthcare and a non-healthcare setting," noted Dr. George Evetts, Consultant in Anesthesia & Intensive Care Medicine at Frimley Park Hospital.

Related Links:
University of Surrey

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Sample Transportation System
Tempus1800 Necto

Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more